文献速递妇科

抗生素、质子泵抑制剂、H2受体拮抗剂及类固醇对接受PARP抑制剂治疗的卵巢癌患者生存的影响

The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy.
PubMed 文献 · Gynecol Oncol · 2025-05-31

本回顾性研究纳入237例接受269种PARP抑制剂方案的卵巢癌患者,评估抗生素、质子泵抑制剂、H2受体拮抗剂及类固醇对无进展生存期的影响。结果显示这些合并用药与生存恶化无关,抗生素使用虽在单因素分析中与中位PFS改善相关(10 vs 7个月;p=0.049),但多因素分析后失去显著性。

要点

  • HRP/未知状态患者的中位PFS显著差于BRCA突变/HRD患者(6 vs 11个月;p<0.001)。
  • 抗生素、PPI、H2RA及类固醇的使用与接受PARP抑制剂患者的PFS恶化无关。
  • 抗生素使用在单因素分析中与中位PFS改善相关(10 vs 7个月;p=0.049),但多因素分析后不显著。

核心结论

  • 在这项回顾性分析中,合并用药与接受PARP抑制剂的卵巢癌患者生存恶化无关;抗生素使用虽与生存改善相关,但校正混杂因素后不显著。

研究设计与样本

  • 回顾性研究,纳入237例接受269种PARP抑制剂方案的卵巢癌患者,分析 demographics、临床病理特征及治疗结局。
  • 采用Cox比例风险模型评估PFS危险因素,Kaplan-Meier分析及log-rank检验评估基于抗生素使用的生存差异。

主要发现

  • 237例患者中79.6%在复发场景接受PARP抑制剂;治疗时21.6%使用抗生素,15.6%使用PPI,11.2%使用H2RA,63.9%使用类固醇。
  • HRP/未知状态患者的中位PFS显著差于BRCA突变/HRD患者(6 vs 11个月;p<0.001)。
  • 抗生素使用与中位PFS改善相关(10 vs 7个月;p=0.049),但多因素分析后失去显著性。
  • PPI、H2RA及类固醇对PFS无影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Antibiotics (ABX) have been linked to reduced survival in ovarian cancer (OC) when administered before or during platinum-based chemotherapy. This study evaluates the impact of ABX, proton pump inhibitors (PPI), H2-receptor antagonists (H2RA), and steroids on progression-free survival (PFS) in OC patients receiving poly-ADP-ribose polymerase inhibitors (PARPi). METHODS: This retrospective study examined OC patients who used ABX, PPI, H2RA, or steroids before or during PARPi therapy. Demographics, clinicopathologic characteristics, and treatment outcomes were analyzed. Cox proportional hazards models assessed risk factors for PFS, and Kaplan-Meier analysis with log-rank testing evaluated survival differences based on ABX use. RESULTS: Among 237 patients treated with 269 PARPi regimens, most received PARPi in the recurrent setting (79.6 %). At the time of PARPi therapy, 21.6 % used ABX, 15.6 % PPI, 11.2 % H2RA, and 63.9 % steroids. Patients with HRP/unknown status had significantly worse median PFS than those with BRCA-mutated/HRD (6 vs. 11 months; p < 0.001). ABX use correlated with improved median PFS (10 vs. 7 months; p = 0.049) but lost significance in multivariate analysis. PPI, H2RA, and steroids had no impact on PFS. CONCLUSION: In this retrospective analysis, concurrent medications were not associated with worsened survival outcomes in OC patients receiving PARPi. Further, while ABX use during PARPi therapy was associated with improved survival this was not significant after adjusting for confounders.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kistenfeger Q, Haight PJ, Levine M, et al. The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy. Gynecol Oncol. 2025. PMID: 40450912. doi:10.1016/j.ygyno.2025.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。